SABCS 2022: When Treating Breast Cancer, Less May Be More
Cancer treatment is a double-edged sword. Intense or multi-pronged treatment may lead to better killing of tumor cells, but...
Progress Against Cancer
Cancer treatment is a double-edged sword. Intense or multi-pronged treatment may lead to better killing of tumor cells, but...
The new AKT inhibitor doubled progression-free survival when added to treatment with Faslodex.
Study finds pausing endocrine therapy is safe for early-stage breast cancer patients eager to expand their families.
Black breast cancer patients had worse outcomes in a recent study, even when cancer features aligned with white patients.
By Kaleem Zaidi, PhDAACR Executive Office The year 2022 marked significant progress against cancer, thanks to advances in cancer...
AACR patient advocate forum addresses developments in cancer early detection tests.
For the sixth time since 2015, researchers, clinicians, drug developers, patient advocates, and other stakeholders convened at the International...
What is cancer, exactly? For the most part, experts agree. The National Cancer Institute defines cancer as “a disease...
Five years after the FDA approved the first CAR T-cell therapy, use of the treatment has expanded to many...
New studies probe how to match targeted therapies to children with cancer.